Anita Gandhi,Patrick Hagner,Anke Klippel,Michael Pourdehnad,Matthew William Burnell Trotter,Ming Lei
申请号：
US15227877
公开号：
US20170038387A1
申请日:
2016.08.03
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A method of identifying a subject having chronic lymphocytic leukemia (CLL) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having CLL； administering 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A) to the first sample and administering lenalidomide to the second sample； determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample； and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.
